Pasar al contenido principal

IMPACTO DEL DAÑO HEPATICO DESARROLLADO EN LA ENFEMEDAD DE WILSON SOBRE LA SEGURIDAD Y EFICACIA DE LA TER. GEN. E IDENTIFICACION DE MECANISMOS MOLECULARES DE DAÑO POR CU

PID2021-124455OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Profile of plasma microRNAs as a potential biomarker of Wilson&apos, s disease

  • Sánchez-Monteagudo, Ana
  • Ripollés, Edna
  • Murillo, Oihana
  • Domènech, Sofia
  • Álvarez-Sauco, María
  • Girona, Eva
  • Sastre-Bataller, Isabel
  • Bono, Ariadna
  • García-Villarreal, Luis
  • Tugores, Antonio
  • García-García, Francisco
  • González-Aseguinolaza, Gloria
  • Berenguer, Marina
  • Espinós-Armero, Carmen
[EN] Background: Wilson's disease (WD) is a rare condition resulting from autosomal recessive mutations in ATP7B, a copper transporter, manifesting with hepatic, neurological, and psychiatric symptoms. Timely diagnosis and appropriate treatment yield a positive prognosis, while delayed identification and/or insufficient therapy lead to a poor outcome. Our aim was to establish a prognostic method for WD by characterising biomarkers based on circulating microRNAs. Methods: We conducted investigations across three cohorts: discovery, validation (comprising unrelated patients), and follow-up (revisiting the discovery cohort 3 years later). All groups were compared to age- and gender-matched controls. Plasma microRNAs were analysed via RNA sequencing in the discovery cohort and subsequently validated using quantitative PCR in all three cohorts. To assess disease progression, we examined the microRNA profile in Atp7b-/- mice, analysing serum samples from 6 to 44 weeks of age and liver samples at three time points: 20, 30, and 40 weeks of age. Results: In patients, elevated levels of the signature microRNAs (miR-122-5p, miR-192-5p, and miR-885-5p) correlated with serum activities of aspartate transaminase, alanine aminotransferase and gamma-glutamyl transferase. In Atp7b-/- mice, levels of miR-122-5p and miR-192-5p (miR-885-5p lacking a murine orthologue) increased from 12 weeks of age in serum, while exhibiting fluctuations in the liver, possibly attributable to hepatocyte regenerative capacity post-injury and the release of hepatic microRNAs into the bloodstream. Conclusions: The upregulation of the signature miR-122-5p, miR-192-5p, and miR-885-5p in patients and their correlation with liver disease progression in WD mice support their potential as biomarkers of WD., are in debt with the patients and their families for agreeing to participate in this study. The authors also thank Aida Regi-Cosculluela and Faustino Gimenez-Felices, Spanish association of patients with Wilson disease (AEFE Wilson), always willing to bring science closer to patients and their families. This study has been funded by the Fundacio Per Amor a l'Art (FPAA); by the Instituto de Salud Carlos III (ISCIII) through the projects PI18/00147 and PI21/00103 to CE, PI21/00313 to OM, and INT20/00061 to MB, and co-funded by the European Union; by MCIN/AEI/https://doi.org/10.13039/501100011033 and by "ERDF A way of, making Europe" through the project PID2021-124455OB-I00 to GGA; and by the Centro de Investigacion Biomedica en Red (CIBER) through the project CB06/04/0065 to MB. Part of the equipment employed in this work was funded by Generalitat Valenciana and co-financed with ERDF (OP ERDF of Comunitat Valenciana 2014-2020). ER has a PhD fellowship from the Generalitat Valenciana [CIACIF/2021/252].